Should I Buy BNR? BNR 2026 Analysis

Should You Buy Burning Rock Biotech Ltd (BNR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

35.750

1 Day change

1.02%

52 Week Range

41.720

Analysis Updated At

2026/01/23

Burning Rock Biotech Ltd (BNR) is not a strong buy for a beginner investor with a long-term strategy at this moment. The technical indicators show a bullish trend, but the overbought RSI suggests potential short-term price correction. The company's financial performance in the latest quarter shows declining net income and EPS, which raises concerns about profitability. Additionally, there are no recent positive news catalysts, and analyst sentiment is cautious with no upgrades or strong buy recommendations. Given the investor's long-term focus, it would be prudent to wait for better financial performance or more favorable market conditions before investing.

Technical Analysis

The MACD is positive and expanding, indicating bullish momentum. The RSI is at 85.631, signaling an overbought condition. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at R1: 38.535 and R2: 43.537, while support levels are at S1: 22.343 and S2: 17.342.

Options Data

Positive Catalysts

2026/01/23 04:55:22

Bullish technical indicators such as positive MACD and bullish moving averages.

Neutral/Negative Catalysts

2026/01/23 04:55:22

Overbought RSI indicating potential short-term correction, declining net income (-53.12% YoY) and EPS (-54.29% YoY), no recent positive news or congress trading data, and cautious analyst sentiment.

Financial Performance

In Q3 2025, revenue increased by 2.31% YoY to 131,617,000, but net income dropped significantly by 53.12% YoY to -16,758,000. EPS also declined by 54.29% YoY to -0.16. Gross margin improved by 5.18% YoY to 75.1.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent analyst ratings are cautious. Morgan Stanley downgraded the stock to Underweight with a price target of EUR 50, down from EUR 63. Berenberg lowered its price target to EUR 48 from EUR 51 and maintained a Hold rating.

Analyst Rating

Wall Street analysts forecast BNR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNR is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 35.390

Low

Averages

High

Current: 35.390

Low

Averages

High

Morgan Stanley

Annelies Vermeulen

Equal Weight -> Underweight

downgrade

AI Analysis

2026-01-06

Reason

Morgan Stanley

Annelies Vermeulen

Price Target

AI Analysis

2026-01-06

downgrade

Equal Weight -> Underweight

Reason

Morgan Stanley analyst Annelies Vermeulen downgraded Brenntag to Underweight from Equal Weight with a price target of EUR 50, down from EUR 63. The firm adjusted rating in the European business services group as part of its 2026 outlook. The analyst is cautious on the staffers and chemical distribution. Morgan Stanley's preferred stocks for 2026 are Experian, Diploma, Rentokil, Verisure, Bureau Veritas and ISS.

Berenberg

Hold

downgrade

2025-12-10

Reason

Berenberg

Price Target

2025-12-10

downgrade

Hold

Reason

Berenberg lowered the firm's price target on Brenntag to EUR 48 from EUR 51 and keeps a Hold rating on the shares.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BNR

Unlock Now

BNR Should I Buy

BNR Should I Buy

Should You Buy Burning Rock Biotech Ltd (BNR) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch